https://www.selleckchem.com/products/Oridonin(Isodonol).html 50 (95% CI 1.13-1.97)] (E-value for point estimate=2.37) and during both trimesters of pregnancy [RR 1.41 (95% CI 1.03-1.89)] (E-value for point estimate=2.17). However, we found insufficient statistical evidence for an association between paternal smoking during pregnancy and risk of tobacco smoking in offspring [RR 1.18 (95% CI 0.84-1.67)]. Maternal prenatal tobacco exposure was associated with an increased risk of tobacco smoking in offspring at the age of 17years. Tobacco smoking cessation at the early stages of gestation may reduce the risk of tobacco smoking in the next generation. Maternal prenatal tobacco exposure was associated with an increased risk of tobacco smoking in offspring at the age of 17 years. Tobacco smoking cessation at the early stages of gestation may reduce the risk of tobacco smoking in the next generation. Treatment completion is associated with abstinence outcomes in smoking cessation interventions. Previous research has stated that anxiety sensitivity (AS) is associated with smoking-related variables and smoking-cessation outcomes. To date, research has not examined the interaction between AS and treatment completion on smoking-cessation outcomes over time. This study aims to examine the main and the interactive effects of treatment completion and AS (total score and specific dimensions) on smoking-cessation outcomes at 3-, 6-, and 12-month follow-ups. The sample consisted of 210 smokers enrolled in an eight-session smoking-cessation cognitive-behavioral treatment (62.1% women; M =45.2, SD=11.0). Participants were classified as completers (attended the eight treatment sessions) and non-completers (attended≤7 sessions). Abstinence was biochemically confirmed. Main effects indicated that completers had a higher likelihood of being abstinent over time when compared to non-completers. Regarding AS, those with greater AS-Physical Concerns had lower abstinence rates. Besides, a sign